BioMarin Pharmaceutical - BMRN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $113.43
  • Forecasted Upside: 33.81 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$84.77
▼ -0.29 (-0.34%)

This chart shows the closing price for BMRN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioMarin Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BMRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BMRN

Analyst Price Target is $113.43
▲ +33.81% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $113.43, with a high forecast of $135.00 and a low forecast of $74.00. The average price target represents a 33.81% upside from the last price of $84.77.

This chart shows the closing price for BMRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 14 contributing investment analysts is to buy stock in BioMarin Pharmaceutical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/4/2022
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/2/2022

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/28/2022Stifel NicolausBoost Target$104.00Low
9/13/2022WedbushReiterated RatingNeutral$74.00Low
8/26/2022Robert W. BairdReiterated RatingOutperform ➝ Outperform$112.00Low
8/9/2022Credit Suisse GroupBoost Target$111.00N/A
8/9/2022Piper SandlerBoost TargetOverweight$125.00 ➝ $128.00Low
8/4/2022Morgan StanleyBoost TargetOverweight$113.00 ➝ $117.00Low
8/4/2022SVB LeerinkBoost TargetOutperform$115.00 ➝ $122.00Low
8/4/2022BarclaysBoost TargetOverweight$112.00 ➝ $125.00Low
7/12/2022Cantor FitzgeraldInitiated CoverageOverweight$110.00N/A
6/28/2022Robert W. BairdReiterated RatingOutperform ➝ Outperform$112.00Low
6/24/2022WedbushReiterated RatingHold$70.00Low
6/13/2022WedbushLower TargetOutperform ➝ Neutral$146.00 ➝ $70.00High
6/6/2022Credit Suisse GroupBoost TargetOutperform$105.00 ➝ $106.00High
5/4/2022Jefferies Financial GroupReiterated RatingBuy ➝ Buy$100.00Low
5/3/2022Stifel NicolausReiterated RatingBuy$96.00Low
4/28/2022WedbushLower Target$155.00 ➝ $147.00High
4/25/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$96.00 ➝ $113.00Medium
4/12/2022Morgan StanleyBoost TargetEqual Weight$90.00 ➝ $96.00Low
2/24/2022WedbushReiterated RatingOutperform$155.00Medium
2/24/2022Piper SandlerBoost TargetOverweight$121.00 ➝ $125.00High
2/18/2022Morgan StanleyReiterated RatingHold$90.00N/A
1/10/2022Truist FinancialBoost Target$125.00 ➝ $135.00High
12/2/2021SVB LeerinkReiterated RatingBuyLow
11/23/2021Robert W. BairdBoost TargetOutperform$101.00 ➝ $112.00Low
11/22/2021OppenheimerBoost TargetMarket Perform$84.00 ➝ $95.00Low
11/22/2021GuggenheimBoost TargetBuy$103.00 ➝ $120.00Low
11/22/2021Credit Suisse GroupBoost TargetOutperform$100.00 ➝ $105.00Low
11/22/2021JPMorgan Chase & Co.Boost TargetOverweight$129.00 ➝ $135.00Low
11/22/2021Morgan StanleyBoost TargetEqual Weight$82.00 ➝ $90.00Low
11/22/2021SVB LeerinkBoost TargetOutperform$112.00 ➝ $115.00Low
11/22/2021William BlairUpgradeMarket Perform ➝ OutperformMedium
11/15/2021SVB LeerinkBoost TargetOutperform$108.00 ➝ $112.00Low
10/28/2021WedbushReiterated RatingOutperform$152.00Medium
10/28/2021Credit Suisse GroupLower TargetOutperform$102.00 ➝ $100.00High
10/28/2021Piper SandlerBoost TargetOverweight$119.00 ➝ $121.00High
9/14/2021SVB LeerinkReiterated RatingBuyLow
9/9/2021Stifel NicolausUpgradeHold ➝ Buy$86.00 ➝ $96.00High
9/7/2021Royal Bank of CanadaReiterated RatingHold$88.00High
9/7/2021WedbushReiterated RatingBuy$152.00High
8/30/2021WedbushBoost TargetOutperform$141.00 ➝ $152.00Low
7/29/2021WedbushReiterated RatingBuy$141.00Medium
7/29/2021Jefferies Financial GroupInitiated CoverageBuy$112.00Medium
7/29/2021Royal Bank of CanadaBoost TargetSector Perform$87.00 ➝ $88.00High
7/29/2021Piper SandlerBoost TargetOverweight$112.00 ➝ $119.00Medium
7/16/2021WedbushReiterated RatingBuy$141.00Medium
7/11/2021SVB LeerinkInitiated CoverageBuy$83.62Medium
7/2/2021SVB LeerinkReiterated RatingBuyHigh
6/29/2021WedbushReiterated RatingBuy$141.00Low
4/28/2021WedbushReiterated RatingBuy$139.00Low
4/26/2021Credit Suisse GroupInitiated CoverageOutperform$102.00Medium
4/19/2021Morgan StanleyLower TargetEqual Weight$85.00 ➝ $82.00Low
3/23/2021WedbushReiterated RatingOutperform$139.00Medium
3/1/2021Evercore ISIUpgradeIn-Line ➝ Outperform$90.00 ➝ $100.00Low
3/1/2021Robert W. BairdReiterated RatingBuyLow
1/11/2021Robert W. BairdBoost TargetPositive ➝ Outperform$100.00 ➝ $110.00High
11/6/2020SVB LeerinkLower TargetOutperform$113.00 ➝ $108.00High
9/10/2020Truist FinancialLower Target$130.00 ➝ $125.00Low
9/10/2020WedbushReiterated RatingBuyHigh
8/21/2020Morgan StanleyLower TargetEqual Weight$125.00 ➝ $85.00Low
8/20/2020Truist FinancialLower Target$143.00 ➝ $130.00Low
8/20/2020OppenheimerLower Target$116.00 ➝ $88.00Low
8/20/2020Jefferies Financial GroupLower TargetBuy$138.00 ➝ $118.00Medium
8/20/2020William BlairReiterated RatingOutperform ➝ Market PerformMedium
8/19/2020CitigroupDowngradeBuy ➝ Neutral$148.00 ➝ $86.00Medium
8/19/2020WedbushReiterated RatingBuy$136.00Medium
8/19/2020SVB LeerinkLower TargetOutperform$140.00 ➝ $113.00High
8/19/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$123.00 ➝ $92.00High
8/19/2020Stifel NicolausDowngradeBuy ➝ Hold$127.00 ➝ $100.00High
8/14/2020The Goldman Sachs GroupBoost Target$172.00 ➝ $218.00Low
8/6/2020BMO Capital MarketsBoost TargetMarket Perform$94.00 ➝ $108.00Low
8/5/2020OppenheimerInitiated CoverageHold$116.00Low
8/5/2020WedbushReiterated RatingBuy$146.00Low
8/5/2020BarclaysBoost Target$125.00 ➝ $135.00Low
8/5/2020Piper SandlerBoost Target$120.00 ➝ $133.00Low
8/5/2020Credit Suisse GroupReiterated RatingBuy$128.00Medium
8/5/2020JPMorgan Chase & Co.Boost TargetOverweight$140.00 ➝ $156.00Low
8/5/2020SVB LeerinkBoost TargetOutperform$130.00 ➝ $140.00Low
7/28/2020JPMorgan Chase & Co.Reiterated RatingBuy$140.00Low
7/27/2020WedbushReiterated RatingBuy$145.00Low
7/24/2020Robert W. BairdBoost Target$125.00 ➝ $140.00Low
7/8/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$125.00Low
7/6/2020CitigroupBoost TargetBuy$105.00 ➝ $148.00Low
6/21/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
6/18/2020WedbushReiterated RatingBuy$145.00High
6/18/2020SunTrust BanksBoost Target$109.00 ➝ $143.00Low
6/18/2020OppenheimerBoost TargetPerformer$88.00 ➝ $95.00High
6/17/2020SunTrust BanksBoost TargetBuy$109.00 ➝ $143.00Medium
6/10/2020Bank of AmericaBoost TargetBuy$120.00 ➝ $130.00Low
6/5/2020BarclaysBoost Target$105.00 ➝ $125.00Medium
6/3/2020WedbushReiterated RatingBuy$145.00Medium
6/1/2020Credit Suisse GroupReiterated RatingBuy$128.00Low
5/10/2020CfraReiterated RatingBuy$115.00Low
5/7/2020Credit Suisse GroupReiterated RatingBuy$128.00High
5/1/2020WedbushReiterated RatingOutperform$145.00Low
5/1/2020William BlairReiterated RatingBuyLow
4/30/2020SunTrust BanksLower TargetBuy$110.00 ➝ $109.00High
4/30/2020NomuraReiterated RatingHold$77.00High
4/30/2020Credit Suisse GroupLower TargetOutperform$131.00 ➝ $128.00High
4/30/2020OppenheimerReiterated RatingHold$88.00High
4/6/2020WedbushReiterated RatingBuy$164.00High
3/24/2020WedbushReiterated RatingOutperformHigh
3/3/2020Morgan StanleyBoost TargetOverweight$120.00 ➝ $125.00Low
3/2/2020Nomura SecuritiesReiterated RatingHold$77.00Medium
3/1/2020WedbushReiterated RatingBuy$164.00High
2/28/2020CitigroupBoost Target$95.00 ➝ $105.00Medium
2/28/2020BarclaysReiterated RatingBuy$100.00Medium
2/27/2020OppenheimerBoost Target$88.00 ➝ $80.00Medium
2/23/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
2/21/2020WedbushReiterated RatingOutperform$158.00 ➝ $175.00Low
1/27/2020BMO Capital MarketsInitiated CoverageMarket Perform$94.00Medium
1/24/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$111.00 ➝ $113.00Low
1/21/2020WedbushReiterated RatingBuy$158.00Low
1/2/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
12/23/2019WedbushReiterated RatingBuy$158.00N/A
12/17/2019WedbushReiterated RatingBuy$158.00Low
12/16/2019Cantor FitzgeraldReiterated RatingBuy$129.00Low
12/16/2019Royal Bank of CanadaReiterated RatingHold$111.00Low
12/16/2019CowenReiterated RatingBuy$150.00Medium
12/13/2019Robert W. BairdReiterated RatingBuy$120.00High
12/11/2019Bank of AmericaReiterated RatingBuy$90.00High
11/27/2019BarclaysUpgradeEqual Weight ➝ Overweight$86.00 ➝ $98.00Medium
11/22/2019WedbushReiterated RatingBuy$157.00Low
11/15/2019William BlairReiterated RatingBuyLow
11/12/2019SunTrust BanksInitiated CoverageBuy$110.00Medium
10/30/2019CitigroupReiterated RatingBuy$120.00 ➝ $95.00Low
10/25/2019WedbushBoost TargetOutperform$128.00 ➝ $152.00Low
10/24/2019Nomura SecuritiesLower Target$93.00 ➝ $77.00Medium
10/24/2019BarclaysLower TargetEqual Weight$95.00 ➝ $86.00Medium
10/21/2019Cantor FitzgeraldSet TargetBuy$129.00High
10/16/2019Bank of AmericaInitiated CoverageBuy$90.00Low
9/26/2019WedbushSet TargetBuy$128.00High
9/13/2019Piper Jaffray CompaniesSet TargetBuy$120.00Medium
9/13/2019Stifel NicolausSet TargetBuy$108.00Medium
8/5/2019JPMorgan Chase & Co.Reiterated RatingBuy$133.00High
7/10/2019WedbushReiterated RatingOutperform$128.00Medium
6/19/2019WedbushReiterated RatingOutperform$128.00Low
6/2/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
5/28/2019WedbushReiterated RatingBuy$128.00Medium
5/23/2019CitigroupReiterated RatingBuy ➝ BuyLow
4/26/2019Robert W. BairdSet TargetBuy$120.00Low
4/26/2019WedbushBoost TargetOutperform ➝ Outperform$127.00 ➝ $128.00Low
4/26/2019Cantor FitzgeraldReiterated RatingBuy$131.00Low
4/9/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$110.00Low
4/2/2019Robert W. BairdSet TargetBuy$120.00Low
4/2/2019Cantor FitzgeraldReiterated RatingBuy$131.00Low
3/4/2019Cantor FitzgeraldBoost TargetPositive ➝ Overweight$131.00Medium
2/26/2019WedbushSet TargetBuy$127.00Low
2/25/2019SunTrust BanksLower TargetBuy$117.00Medium
2/24/2019BarclaysReiterated RatingHold$95.00High
2/22/2019OppenheimerLower Target$92.00 ➝ $81.00Medium
2/7/2019WedbushReiterated RatingOutperform$127.00Low
1/8/2019OppenheimerSet TargetHold$92.00Medium
1/7/2019CowenReiterated RatingBuyMedium
1/7/2019Cantor FitzgeraldReiterated RatingBuy$126.00Low
1/2/2019Raymond JamesDowngradeOutperform ➝ Market Perform$83.16Medium
12/17/2018GuggenheimInitiated CoverageNeutralHigh
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformMedium
12/13/2018OppenheimerInitiated CoverageHold$92.00Low
11/28/2018Cantor FitzgeraldSet TargetBuy$126.00Medium
11/14/2018WedbushSet TargetBuy$127.00Low
11/4/2018Cantor FitzgeraldReiterated RatingBuy$126.00Low
10/29/2018WedbushSet TargetBuy$127.00Medium
10/26/2018Raymond JamesBoost TargetOutperform ➝ Buy$113.00 ➝ $114.00Low
10/26/2018Cantor FitzgeraldSet TargetBuy$126.00Medium
10/16/2018Jefferies Financial GroupBoost TargetFair Value ➝ Buy$125.00High
10/15/2018Cantor FitzgeraldSet TargetBuy$126.00High
10/7/2018Cantor FitzgeraldSet TargetBuy$126.00Medium
9/28/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$126.00Low
9/13/2018WedbushSet TargetBuy$120.00Low
8/9/2018CitigroupBoost TargetBuy ➝ Buy$108.00 ➝ $120.00Low
8/6/2018WedbushReiterated RatingOutperform ➝ Outperform$115.00 ➝ $120.00High
8/5/2018JPMorgan Chase & Co.Reiterated RatingBuy$135.00High
8/5/2018BarclaysReiterated RatingEqual Weight ➝ Hold$95.00 ➝ $98.00High
8/3/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$113.00 ➝ $115.00High
8/3/2018Stifel NicolausBoost TargetBuy ➝ Buy$102.00 ➝ $109.00High
7/9/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$120.00 ➝ $122.00Low
6/20/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
5/31/2018JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$127.00 ➝ $133.00Low
5/29/2018CitigroupBoost TargetBuy$108.00Low
5/25/2018WedbushBoost TargetOutperform ➝ Outperform$112.00 ➝ $115.00Low
5/25/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$116.00 ➝ $120.00Low
5/15/2018WedbushReiterated RatingOutperform$112.00Low
5/7/2018SVB LeerinkBoost TargetOutperform$132.00 ➝ $145.00Medium
4/30/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$112.00 ➝ $113.00High
4/30/2018WedbushLower TargetOutperform$112.00 ➝ $110.00Medium
4/30/2018Sanford C. BernsteinLower TargetMarket Perform$97.00 ➝ $92.00Medium
4/26/2018JPMorgan Chase & Co.Set TargetBuy$127.00Medium
3/29/2018Credit Suisse GroupReiterated RatingBuy$116.00Medium
3/12/2018WedbushReiterated RatingOutperform$110.00Medium
3/2/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$113.00 ➝ $116.00High
2/27/2018Royal Bank of CanadaReiterated RatingHold$94.00Medium
2/25/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
2/25/2018Credit Suisse GroupReiterated RatingBuy$113.00Low
2/23/2018Morgan StanleyLower TargetOverweight ➝ Overweight$115.00 ➝ $112.00Medium
2/23/2018Stifel NicolausLower TargetBuy ➝ Buy$105.00 ➝ $102.00High
2/23/2018SVB LeerinkLower TargetOutperform ➝ Outperform$142.00 ➝ $132.00High
2/23/2018BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$119.00 ➝ $125.00High
2/23/2018Deutsche Bank AktiengesellschaftSet TargetBuy ➝ Buy$119.00 ➝ $124.00High
1/24/2018JPMorgan Chase & Co.Lower TargetOverweight ➝ Outperform$131.00 ➝ $129.00Medium
1/18/2018Piper Jaffray CompaniesReiterated RatingBuy$114.00Low
1/18/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$113.00Low
12/22/2017WedbushReiterated RatingOutperform$110.00Medium
12/15/2017The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyHigh
12/14/2017WedbushUpgradeNeutral ➝ Outperform$110.00Low
12/11/2017SunTrust BanksBoost TargetBuy$130.00High
11/27/2017JPMorgan Chase & Co.Set TargetBuy$131.00Medium
11/15/2017WedbushReiterated RatingNeutral$108.00N/A
10/29/2017JPMorgan Chase & Co.Set TargetBuy$130.00N/A
10/27/2017BMO Capital MarketsBoost TargetOutperform$117.00 ➝ $119.00N/A
10/27/2017Stifel NicolausLower TargetBuy$107.00 ➝ $105.00N/A
10/20/2017BMO Capital MarketsReiterated RatingBuy$117.00N/A
10/19/2017SunTrust BanksSet TargetBuy$115.00N/A
10/19/2017SVB LeerinkReiterated RatingOutperform$136.00 ➝ $142.00N/A
10/19/2017Credit Suisse GroupReiterated RatingOutperform$114.00 ➝ $124.00N/A
10/6/2017The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$129.00N/A
10/6/2017Morgan StanleyReiterated RatingOverweight$115.00 ➝ $117.00N/A
(Data available from 10/2/2017 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/6/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/5/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/5/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
6/4/2022
  • 7 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/4/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
8/3/2022
  • 1 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/2/2022
  • 2 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/2/2022

Current Sentiment

  • 2 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
BioMarin Pharmaceutical logo
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Read More

Today's Range

Now: $84.77
Low: $84.51
High: $86.75

50 Day Range

MA: $89.76
Low: $82.16
High: $96.94

52 Week Range

Now: $84.77
Low: $70.73
High: $97.76

Volume

1,437,084 shs

Average Volume

912,510 shs

Market Capitalization

$15.72 billion

P/E Ratio

326.05

Dividend Yield

N/A

Beta

0.32

Frequently Asked Questions

What sell-side analysts currently cover shares of BioMarin Pharmaceutical?

The following equities research analysts have issued research reports on BioMarin Pharmaceutical in the last twelve months: Barclays PLC, Cantor Fitzgerald, Credit Suisse Group AG, Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, TheStreet, Truist Financial Co., Wedbush, and William Blair.
View the latest analyst ratings for BMRN.

What is the current price target for BioMarin Pharmaceutical?

14 Wall Street analysts have set twelve-month price targets for BioMarin Pharmaceutical in the last year. Their average twelve-month price target is $113.43, suggesting a possible upside of 33.8%. JPMorgan Chase & Co. has the highest price target set, predicting BMRN will reach $135.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $74.00 for BioMarin Pharmaceutical in the next year.
View the latest price targets for BMRN.

What is the current consensus analyst rating for BioMarin Pharmaceutical?

BioMarin Pharmaceutical currently has 2 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BMRN will outperform the market and that investors should add to their positions of BioMarin Pharmaceutical.
View the latest ratings for BMRN.

What other companies compete with BioMarin Pharmaceutical?

How do I contact BioMarin Pharmaceutical's investor relations team?

BioMarin Pharmaceutical's physical mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company's listed phone number is (415) 506-6700 and its investor relations email address is [email protected] The official website for BioMarin Pharmaceutical is www.bmrn.com. Learn More about contacing BioMarin Pharmaceutical investor relations.